DocDollars

Axsome Therapeutics, Inc.

NY · United States · Reporting entity ID 100001111886

Total reported 2019–2025
$67.5M
#135 of 2,960 reporting companies — 0.1% of all reported industry payments
$42.8M in general payments across 316,908 records, plus $24.7M in research funding across 1,030 records.

How it breaks down

General payments $42,779,386
Research funding $24,700,487

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Axsome Therapeutics, Inc. reported $67.5M to US doctors and teaching hospitals from 2019 to 2025, ranking #135 of 2,960 reporting companies. 37% of that was research funding and 63% general payments such as consulting, speaking, food and travel. 316,908 general payment records and 1,030 research records were filed.

Common questions about Axsome Therapeutics, Inc.

How much has Axsome Therapeutics, Inc. paid US doctors?

Axsome Therapeutics, Inc. reported $67,479,872 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $42,779,386 in general payments, $24,700,487 in research funding.

How does Axsome Therapeutics, Inc. rank among drug and device companies?

It ranks #135 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Axsome Therapeutics, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.